Stock 300267 HUNAN ER-KANG PHARMACEUTICAL CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Hunan Er-Kang Pharmaceutical Co., Ltd

Equities

300267

CNE100001781

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-06-12 EDT 		5-day change 1st Jan Change
2.25 CNY -2.60% Intraday chart for Hunan Er-Kang Pharmaceutical Co., Ltd -1.32% -29.91%
04-26 Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-24 Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2022 Final Profit Distribution, Payable on 09 June 2023
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Approves 2022 Profit Distribution Plan
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2022
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
CI
ER-KANG Pharma Earmarks $140 Million for Lithium Carbonate Factory; Shares Gain 7%
MT
Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Announces Profit Distribution Proposal for 2021
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Hunan Er-Kang Pharmaceutical Co., Ltd signed equity purchase agreement to acquire Henan Yuxingkang Pharmaceutical Co., Ltd. from Shuai Fangwen and Cao Zaiyun for CNY 44 million.
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Hunan Er-Kang Pharmaceutical Co., Ltd(XSEC:300267) added to S&P Global BMI Index
CI
Hunan Er-Kang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300267 Stock
  4. News Hunan Er-Kang Pharmaceutical Co., Ltd